

Francois Moisan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8464521/publications.pdf>

Version: 2024-02-01

15
papers

287
citations

1039880

9
h-index

1281743

11
g-index

15
all docs

15
docs citations

15
times ranked

508
citing authors

#	ARTICLE	IF	CITATIONS
1	Is Infantile Hemangioma a Neuroendocrine Tumor?. International Journal of Molecular Sciences, 2022, 23, 5140.	1.8	4
2	Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	25
3	Decreased CCN3 in Systemic Sclerosis Endothelial Cells Contributes to Impaired Angiogenesis. Journal of Investigative Dermatology, 2020, 140, 1427-1434.e5.	0.3	12
4	Is Hyperpigmentation in Systemic Sclerosis a Perivascular Dermal Tattoo?. Journal of Investigative Dermatology, 2020, 140, 2308-2312.e2.	0.3	0
5	UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis. Oncogenesis, 2019, 8, 52.	2.1	15
6	Loss of Epidermal HIF-1 α Blocks UVB-Induced Tumorigenesis by Affecting DNA Repair Capacity and Oxidative Stress. Journal of Investigative Dermatology, 2019, 139, 2016-2028.e7.	0.3	11
7	Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition. British Journal of Cancer, 2017, 116, 1318-1328.	2.9	51
8	043 Mechanism of action of propranolol in Infantile Hemangioma: New insights from a xenograft model. Journal of Investigative Dermatology, 2016, 136, S168.	0.3	0
9	Enhancement of paclitaxel and carboplatin therapies by Δ CCL2 blockade in ovarian cancers. Molecular Oncology, 2014, 8, 1231-1239.	2.1	85
10	Mast cells as possible targets of propranolol therapy: an immunohistological study of beta-adrenergic receptors in infantile haemangiomas. Histopathology, 2014, 65, 436-439.	1.6	13
11	Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis, 2012, 33, 962-968.	1.3	13
12	Abstract 817: Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers. , 2012, , .		2
13	Abstract 2699: ERCC5 (XPG) status and clinical activity of trabectedin in patients with advanced soft-tissue sarcoma. , 2010, , .		0
14	Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel. Pharmacogenomics, 2006, 7, 843-852.	0.6	37
15	Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. British Journal of Cancer, 2006, 95, 906-913.	2.9	19